Entresto 24/26 mg is the lowest available dose of a heart failure medication that combines two active ingredients to reduce the risk of cardiovascular death and hospitalization. The FDA approves Entresto for adults with chronic heart failure, with the strongest benefits seen in patients whose heart doesn’t pump as forcefully as it should. It’s also approved for children aged one year and older with similar heart failure symptoms. The 24/26 mg strength is specifically the starting dose for certain patient groups who need a gentler introduction to the medication.
How Entresto Works
Heart failure involves two problems happening at once: blood vessels constrict too tightly, and the body loses its ability to respond to natural hormones that would normally relax those vessels and flush out excess fluid. Entresto tackles both problems simultaneously.
The valsartan component blocks a hormonal system that drives blood vessel constriction and fluid retention. By doing so, it lowers blood pressure, reduces the workload on the heart, and slows down the scarring and thickening of heart tissue that worsens heart failure over time. The sacubitril component works differently. It prevents the breakdown of natural hormones called natriuretic peptides, which help blood vessels relax, promote the kidneys’ ability to flush sodium and water, and quiet down the stress signals that push the heart to overwork. Together, these two mechanisms ease the burden on a failing heart from multiple angles.
Who Starts at the 24/26 mg Dose
The 24/26 mg tablet taken twice daily is the recommended starting point for several specific groups. If you haven’t been taking a blood pressure medication from the ACE inhibitor or ARB family, or if you’ve been on a low dose, your prescriber will likely start you here rather than at the higher 49/51 mg starting dose. Adults 75 and older are also typically started at this lower dose, as are people with low blood pressure (systolic readings around 100 to 110).
Kidney and liver function also factor in. If you have severe kidney impairment or moderate liver impairment, the 24/26 mg dose is the standard starting point. The goal is to give your body time to adjust before gradually increasing the dose. From 24/26 mg twice daily, the dose is typically doubled at intervals until reaching the target of 97/103 mg twice daily, as long as blood pressure and kidney function remain stable.
Evidence for Heart Failure Benefits
The landmark trial that established Entresto’s effectiveness, called PARADIGM-HF, compared it head-to-head against a well-established heart failure drug in over 8,000 patients. The results were significant enough that the trial was stopped early. Among patients taking Entresto, 21.8% experienced cardiovascular death or hospitalization for heart failure, compared to 26.5% in the comparison group. That translates to a 20% reduction in the risk of these outcomes.
Cardiovascular death alone dropped from 16.5% to 13.3% with Entresto. These results helped establish Entresto as one of the four core medications now recommended by cardiology guidelines for heart failure with reduced pumping strength. The current expert consensus from the American College of Cardiology identifies a four-drug combination (which includes Entresto alongside a beta-blocker, a mineralocorticoid antagonist, and an SGLT inhibitor) as the standard that increases both survival and years free from cardiovascular events.
What to Expect When Starting
Because Entresto lowers blood pressure, dizziness and lightheadedness are among the most common early side effects, particularly at the start or when the dose increases. Your prescriber will check your kidney function and potassium levels before you begin and periodically during treatment. Potassium monitoring becomes especially important if you’re also taking potassium-sparing water pills, certain other heart failure medications, potassium supplements, or salt substitutes that contain potassium. If kidney function declines significantly, the dose may be reduced or temporarily paused.
One critical timing rule applies if you’re switching from an ACE inhibitor: you need to wait at least 36 hours after your last ACE inhibitor dose before taking your first Entresto tablet. Taking them too close together raises the risk of a serious allergic-type swelling reaction called angioedema. This washout period does not apply when switching from an ARB, which is a different class of blood pressure medication.
Why the Dose Has Two Numbers
The “24/26” label reflects the two active ingredients in each tablet: 24 mg of sacubitril and 26 mg of valsartan. Every Entresto dose is labeled this way, with the sacubitril amount listed first. The three available strengths are 24/26 mg, 49/51 mg, and 97/103 mg. Your prescriber’s goal is to gradually move you toward the highest tolerated dose, since the clinical benefits in trials were demonstrated at the 97/103 mg twice-daily level. Not everyone reaches that target, and the 24/26 mg dose remains a therapeutic option for people who can’t tolerate higher amounts due to blood pressure drops, kidney changes, or other factors.